Biomarx
Category: AI in Healthcare
An automated genomic diagnostic platform designed to democratize personalized cancer care through rapid, low-cost liquid biopsy analysis. Biomarx was founded in 2025. The company is led by Sean Macfarlane. Based in Belfast, United Kingdom. Team size: 1-10. Total funding raised: £700K. Latest round: Pre-seed (£700K, Mar 2025). Key investors include SFC Capital, Clarendon Fund Managers, TechStart Ventures, University of Strathclyde.
- Founded
- 2025
- Headquarters
- Belfast, United Kingdom
- Team size
- 1-10
- Total funding
- £700K
Value proposition
Replaces complex, expensive, and slow lab-based genome sequencing with a rapid, automated 'kit' format, significantly reducing costs and turnaround times for personalized cancer treatment decisions.
Products and solutions
Automated Genomic Diagnostic Platform, Rapid Liquid Biopsy Diagnostic Kits (Initial focus: NSCLC), Automated Genomic Analysis Software, Point-of-Care Molecular Characterization Tools
Unique value
Shifts liquid biopsy from specialized, high-infrastructure laboratories to a standardized, automated kit format that can be utilized in broader clinical settings without extensive bioinformatics support.
Target customer
Oncology clinics, clinical diagnostic laboratories, hospitals, and national healthcare providers (e.g., NHS).
Industries served
Medtech, Healthcare / Oncology, Biotechnology, Clinical Diagnostics
Technology advantage
Leverages proprietary automation and biosensing technology to bypass the traditional bottlenecks of Next-Generation Sequencing (NGS), offering a scalable and decentralized model for genomic diagnostics.
How they differentiate
Shifts liquid biopsy from a centralized, high-cost laboratory service to a decentralized, automated 'kit' format that can be operated locally by clinics without specialized bioinformatics staff.
Main competitors
Guardant Health, Angle plc, Inivata (NeoGenomics)
Key partnerships
University of Strathclyde (Research & IP Collaboration), SFC Capital (Lead Investor), Clarendon Fund Managers, InterTradeIreland (Seedcorn Competition Winner), TechStart Ventures
Notable customers
University of Strathclyde (Research Partner), NHS (Target Healthcare Provider)
Major milestones
Winner of the Northern Ireland Deep Tech category in InterTradeIreland's Seedcorn Competition (2024), Official company incorporation in Belfast (February 2025), Secured £700k Pre-seed funding to advance liquid biopsy platform (March 2025)
Growth metrics
Pre-revenue; currently in product development and clinical validation phase following a successful spin-out collaboration.
Market positioning
Early-stage Medtech disruptor focused on democratizing precision oncology diagnostics.
Geographic focus
United Kingdom and Europe
Patents and IP
IP portfolio developed in collaboration with the University of Strathclyde; specific patent filings are currently managed through the university's commercialization arm.
About Sean Macfarlane
Sean Macfarlane is a Senior Clinical Scientist with extensive experience in medical physics and genomic diagnostics. Prior to founding Biomarx, he served as a Senior Clinical Scientist at DiCroMed and held clinical roles within the NHS. He holds an MSc in Medical Physics from the University of Glasgow and has a strong background in translating in-vitro diagnostics into market-ready products.
Official website: https://biomarx.co.uk/